Skip Navigation



QJM Advance Access published online on December 17, 2008
QJM, doi:10.1093/qjmed/hcn160
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
102/5/305    most recent
hcn160v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Thomson, M. J.
Right arrow Articles by Kaski, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thomson, M. J.
Right arrow Articles by Kaski, J. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Antioxidant treatment for heart failure: friend or foe?

M. J. Thomson1, M. P. Frenneaux2 and J. C. Kaski1

From the 1Cardiovascular Biology Research Centre, Division of Cardiac and Vascular Sciences, St George's, University of London, London and 2Cardiovascular Medicine, Division of Medical Sciences, University of Birmingham, Birmingham, UK

Address correspondence to Prof. J.C. Kaski, Head, Cardiac and Vascular Biology Research Centre, Cardiac and Vascular Sciences, SGUL, Cranmer Terrace, London SW17 0RE, UK. email: jkaski{at}sgul.ac.uk


  Abstract

Increasing studies demonstrate a pivotal role for oxidant stress in the pathophysiology of heart failure (HF). Recent meta-analyses also reveal the potential pitfall of a mono-dimensional antioxidant approach. This review article summarizes the main biological pathways involved in oxidant stress and HF, the possible deleterious nature of certain antioxidant monotherapy and proposes potential antioxidant strategies necessary to challenge specific HF aetiology and progression.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.